2-5 MARCH LEIPZIG L 2020 - 5TH GERMAN PHARM-TOX SUMMIT DER DEUTSCHEN GESELLSCHAFT FÜR EXPERIMENTELLE UND KLINISCHE PHARMAKOLOGIE UND TOXIKOLOGIE ...
←
→
Page content transcription
If your browser does not render page correctly, please read the page content below
5th German Pharm-Tox Summit
86. Jahrestagung
der Deutschen Gesellschaft für Experimentelle und
Klinische Pharmakologie und Toxikologie (DGPT)
in Zusammenarbeit mit der AGAH
© pure-life-pictures - stock.adobe.com
2–5 March
Leipzig l 2020
ProgrAMME
© ShinyChunks l 160792510 l AdobeStock.com
Table of contents
Organisation and imprint . ............................................................................................................... 4
Welcome note ................................................................................................................................. 5
Programme overview
Monday, 2 March ...................................................................................................................... 6
Tuesday, 3 March ...................................................................................................................... 7
Wednesday, 4 March ................................................................................................................ 8
Thursday, 5 March .................................................................................................................... 9
Special meetings .............................................................................................................................. 10
Scientific programme
Monday, 2 March ...................................................................................................................... 11
Tuesday, 3 March ...................................................................................................................... 14
Wednesday, 4 March ................................................................................................................ 22
Thursday, 5 March .................................................................................................................... 32
Poster presentations
Poster session I • Tuesday, 3 March . ....................................................................................... 39
Poster session II • Wednesday, 4 March .................................................................................. 55
Social programme . .......................................................................................................................... 71
General Information ........................................................................................................................ 72
General hints for authors and presenters . ..................................................................................... 74
Index of authors and chairs ............................................................................................................. 75
Media cooperations . ....................................................................................................................... 88
Industrial programme . .................................................................................................................... 88
Sponsors and exhibitors .................................................................................................................. 90
Plan of venue and exhibition area . ................................................................................................. 91
3
ORGANISATION AND IMPRINT Hosting societies Deutsche Gesellschaft für Experimentelle und Klinische Pharmakologie und Toxikologie e. V. (DGPT) www.dgpt-online.de Arbeitsgemeinschaft für Angewandte Humanpharmakologie e. V. (AGAH) www.agah.eu Conference chairs Prof. Dr. Michael Schaefer Universität Leipzig, Medizinische Fakultät Rudolf-Boehm-Institut für Pharmakologie und Toxikologie Vice-chairs Prof. Dr. Achim Aigner Universität Leipzig, Medizinische Fakultät Selbständige Abteilung für Klinische Pharmakologie am Rudolf-Boehm-Institut für Pharmakologie und Toxikologie Prof. Dr. Angelika Richter Universität Leipzig, Veterinärmedizinische Fakultät Institut für Pharmakologie, Pharmazie und Toxikologie Professional congress organiser Conventus Congressmanagement & Marketing GmbH Katharina Szulc/Jenny Gotzmann Phone +49 3641 31 16-314/-376 gpts@conventus.de • www.conventus.de Design/layout Layout krea.tif-studio UG (haftungsbeschränkt) Print siblog – Gesellschaft für Dialogmarketing, Fulfillment & Lettershop mbH Circulation 1.000 Editorial deadline 18 February 2020 4
Welcome note
Dear colleagues and friends,
On behalf of the scientific committee, we warmly welcome all participants of the 5th German Pharm-
Tox-Summit which will be held from March 2–5, 2020 in Leipzig. As in the last years, the Pharm-Tox-
Summit is organized as a joint conference of the member societies of the Deutsche Gesellschaft
für Experimentelle und Klinische Pharmakologie und Toxikologie (DGPT), the Arbeitsgemeinschaft
für Angewandte Humanpharmakologie (AGAH), and also features an integrated Symposium of the
Paul-Martini-Stiftung. Bridging between clinical pharmacology, experimental pharmacology, and
toxicology will be a central goal of this conference and implemented by joint symposia.
Overcoming borders in science, culture and politics is a key feature of Leipzig. The New Augusteum
- venue of the conference - is positioned in midst of the center of this quickly growing and open-
minded city. Leipzig ranks among the most liveable university cities in Germany. We hope you will
enjoy the inspiring atmosphere of Leipzig and make the 5th German Pharm-Tox Summit an exciting
event to foster existing and build up new scientific interactions, collaborations and friendships.
Prof. Dr. Michael Schaefer
Conference chair
Prof. Dr. Angelika Richter & Prof. Dr. Achim Aigner
Vice-chairs
5Programme overview • Monday, 2 March
HS 15 HS 10 HS 16
10:00–17:00
Advanced course in Toxicology
Risikokommunikation
13:00–17:00
Advanced course in Pharmacology
14:00–17:00
Advanced course in Clinical
Pharmacology
Advanced course on drug transporter
models
p. 12 p. 11 p. 13
6Programme overview • Tuesday, 3 March
HS 9 HS 2 HS 4 HS 10 HS 15
08:30–09:30
Short talks
Food Toxicology 09:00–10:30 09:00–10:30 09:00–10:30
Short talks Short talks Short talks
p. 14
Cancer pharmacology G protein‐coupled Ion channels and
09:30–10:30
and treatment receptors membrane
Short talks transporters
Genetic Toxicology
p. 14 p. 15 p. 16 p. 16
10:45–11:00
Welcome note p. 17
11:00–11:45
Plenary lecture I
Pharmacology
p. 17
12:00–13:30 12:00–13:30 12:00–13:30 12:00–13:30 12:00–13:30
Symposium 1 Forum Young Scientist Symposium 2 Symposium 3 Symposium 4
New therapeutic trends Photopharmacology Adenine nucleotides in Air pollution related Microbiota and
and Optogenetics – immunity and chronic inflammatory toxicology – links and
switching on the light in inflammation diseases – from questions
therapy molecular
mechanism to disease
p. 18 p. 18 p. 18 control p. 19 p. 19
13:30–14:15
Get‐together in the foyer p. 71
14:15–15:15
Poster Session I 14:30–16:00
in the foyer Symposium 5 p. 39
15:15–16:00 Mechanisms of
chemosensation –
Meet the company
p. 88 SFB‐TRR 152 p. 19
16:15–17:45 16:15–17:45 16:15–17:45 16:15–17:45
Symposium 6 Symposium 7 Symposium 8 Symposium 9
Stratified Existence and rele‐ Structural dynamics of Antiobesic drugs‐ new
pharmacotherapies in vance of thresholds of G protein‐coupled hopes or riding a dead
oncology genotoxic carcinogens receptors horse?
p. 20 p. 20 p. 20 p. 21
18:00–19:30 18:00–19:30 18:00–19:00
General meeting General meeting General meeting
GT DGP DGKliPha
p. 21
p. 21 p. 21
19:30–20:15
Forum Young Scientists – Social evening
Beyerhaus Leipzig
p. 71
7Programme overview • Wednesday, 4 March
HS 9 HS 2 HS 4 HS 10 HS 15
08:30–09:30
Short talks
Toxic Compounds 09:00–10:30 09:00–10:30 09:00–10:30 09:00–10:30
Short talks Short talks Short talks AGAH Workshop
p. 22
Disease models and Cardiac pharmacology Signal transduction and Part I
09:30–10:30 drug development I and treatment I second messengers
Short talks
Toxins
p. 22 p. 23 p. 24 p. 24 p. 25
11:00–12:30
Symposium 10
Paul‐Martini‐
Symposium
p 25
12:40–14:10 12:40–17:40
12:45–14:45 Workshop AGAH Workshop
Poster Session II Was bedeutet der Part II
in the foyer NKLM2 für die
Pharmakologie/ Introduction to
Toxikologie? physiologically‐based
p. 26 pharmacokinetic (PBPK)
modeling and the Open
Systems Pharmacology
p. 55 (OSP Suite) (PK‐Sim® &
MoBi®)
14:45–16:15 14:45–16:15 14:45–16:15 14:45–16:15
Young Scientists Symposium 11 Symposium 12 Symposium 13
Award selection talks Nanomedicine and ADME research and Joint symposium
Theranostics PGx SFET/GT
p. 27 p. 28 p. 28 p. 28
16:30–17:15
Plenary lecture II
Clinical Pharmacology
p. 29
17:30–18:30 17:30–18:30 17:30–18:30 17:30–18:30 p. 26
Short talks Short talks Short talks Short talks
in vitro Toxicology I CNS / endocrine Cardiac pharmacology Nuclear receptors,
pharmacology and and treatment II enzymes and other
p. 29 treatment p. 29 p. 30 targets p. 31
18:30–19:30
Award ceremony
p. 31
20:00–23:15
Social evening
Ratskeller Leipzig p. 71
8Programme overview • Thursday, 5 March
HS 9 HS 2 HS 4 HS 10
08:30–09:30
Short talks
in vitro toxicology II 09:00–10:30 09:00–10:30 09:00–10:30
Short talks Short talks Short talks
p. 32
Disease models, drug Immunopharmacology / Drug transport,
09:30–10:30 development II inflammation / antiinfectives pharmacokinetics and PK/PD
Short talks modeling
in vitro toxicology III
p. 32 p. 33 p. 34 p. 34
10:45–11:30
Plenary lecture III
Toxicology
p. 35
11:45–13:15 11:45–13:15 11:45–13:15 11:45–13:15
Symposium 14 Symposium 15 Symposium 16 Symposium 17
Uncertainty of toxicological RNAs as pharmacological drugs Joint Symposium SPS/DGPT Cannabis and cannabinoids
assessments or targets
p. 35 p. 36 p. 36 p. 36
13:30–15:00 13:30–15:00 13:30–15:00 13:30–15:00
Symposium 18 Symposium 19 AGAH‐Symposium Symposium 20
Bomben, Minen, weißer Medicine informatics and Clinical and economic Pharmakologie‐historisches
Phosphor – ökologische u. education aspects of medical Forum
gesundheitl. Risiken durch application of biologics
Kriegsaltlasten im Meer
p. 37 p. 37 p. 37 p. 38
15:00–15:30
Closing Ceremony
p. 38
9Special meetings
Monday, 2 March
10:00–17:00 Prüfungen der Toxikologie
SR 205
18:00–21:00 Treffen der AG Planmäßige Professoren der Experimentellen und
Klinischen Pharmakologie und Toxikologie
Location Rittersaal – Eingang von Innenhof
Härtelstraße 16-18 l 04107 Leipzig
Tuesday, 3 March
15:30–16:00 AK „Biogene Toxine“
HS 15
Wednesday, 4 March
09:30–10:30 Fachgruppe Pharmakologie der DPHG
SR 205
10:40–11:40 Editorial Board Meeting in Naunyn-Schmiedebergs Archive’s of Pharmacology
SR 205
14:00–14:30 AK „Respirationstoxikologie/Inhalationstoxikologie“
HS 2
14:00–14:30 AK „Kanzerogenese“
HS 4
13:00–14:00 Präsidiumssitzung und Mitgliederversammlung der Deutschen Gesellschaft
SR 205 für Experimentelle und Klinische Pharmakologie und Toxikologie (DGPT) e. V.
16:30–17:30 AK „Computational Toxicology“ & AK „3R Praxis/Alternativmethoden“
SR 205
Please note, that SR 205 is located in the “Seminargebäude” just next to the “Hörsaalgebäude”.
10Scientific programme • Monday, 2 March
10:00–17:00 Advanced course in Toxicology – Risikokommunikation
HS 10
Chair S. Fiack (Berlin/DE)
10:00 Begrüßung – Einführung/Überblick zum Thema Risikokommunikation
S. Fiack (Berlin/DE), M. Werner (Hofheim a. T./DE)
10:15 Risikokommunikation – Herausforderungen für die Toxikologie
W. Lilienblum (Hannover/DE)
11:00 Fragebogen Risikoquiz/Risikokompetenz
11:45 Risikokommunikation aus Sicht der Behörde – giftig, riskant oder
unbedenklich? Kriterien zielgruppengerechter Risikokommunikation
G.-F. Böl (Berlin/DE)
12:45 Mittagspause/Mitgliederversammlung
des AK Regulatorische Toxikologie & Braune-Tüte-Lunch
13:45 Risikokommunikation aus Sicht der Öffentlichkeitsarbeit/Presse – zwischen
zwei Welten: Erfahrungen im Wissenschaftsjournalismus
H. Wewetzer (Berlin/DE)
14:45 Risikokommunikation aus Sicht der Industrie: Risikokommunikation im
Kosmetik-Sektor – endokrin aktive Stoffe als besondere Herausforderung
W. Schuh (Frankfurt a. M./DE)
15:45 Kaffeepause
16:15 Podiumsdiskussion – Risikokommunikation vor dem Hintergrund der
Transparenz und Glaubwürdigkeit gegenüber der Öffentlichkeit
10:00–17:00 Examinations
SR 205
11Scientific programme • Monday, 2 March
13:00–17:00 Advanced course in Pharmacology
HS 15
Chair R. Seifert (Hannover/DE)
Unter Federführung der Deutschen Gesellschaft für Pharmakologie ist in den letzten
12 Monaten die neue Arzneistoffliste für den Gegenstandskatalog GK2 des Instituts
für Medizinische und Pharmazeutische Prüfungsfragen (IMPP) entwickelt worden.
Diese Liste wird ab dem Jahr 2021 examensrelevant sein und festigt die zentrale
Bedeutung der Pharmakologie und Pharmakotherapie als Querschnittsfächer in der
Medizinerausbildung. Die neue Arzneistoffliste standardisiert die Medizinerausbildung
in Deutschland und wird einen wesentlichen Beitrag zur Qualität der Arzneitherapie,
Patientensicherheit sowie zur verbesserten interprofessionellen Kommunikation leisten.
Der Advanced Course richtet sich an Pharmakologiedozenten aller Erfahrungsstufen
und stellt die neue Arzneistoffliste in allen Aspekten ausführlich dar. Außerdem wird
an Hand eines konkreten pharmakologischen Themas (Psychopharmaka) dargestellt,
wie die Arzneistoffliste leicht und sinnvoll in den Pharmakologieunterricht sowie
die Erstellung von Prüfungsfragen integriert werden kann. Jeder Teilnehmer erhält
zu Kursbeginn ausführliche Kursunterlagen.
13:00 Begrüßung, Einführung, Kursablauf
R. Seifert (Hannover/DE)
13:10 Vorstellung der Arzneistoffliste des IMPP
H. Bachmann (Witten-Herdecke/DE)
13:50 Die Arzneistoffliste aus Sicht des IMPPs
K. Höcherl (Mainz/DE)
14:20 Pharmakologie und Pharmakotherapie im NKLM
R. Maas (Erlangen/DE)
14:50 Kaffeepause
15:10 Umsetzung der Arzneistoffliste und des NKLM in der Pharmakologie – Unterricht
am Beispiel des Themas „Arzneistoffe für die Behandlung neuropsychiatrischer
Erkrankungen”
R. Seifert (Hannover/DE)
16:40 Abschlussdiskussion und Ausgabe der Teilnahmebestätigungen
12Scientific programme • Monday, 2 March
14:00–17:00 Advanced course in Clinical Pharmacology – Advanced course on drug
HS 16 transporter models
14:00 In vitro transport models
J. König (Erlangen/DE)
15:00 Quantification of drug transporter activity in vivo
U. Fuhr (Cologne/DE)
16:00 Transporter quantification
S. Oswald (Greifswald/DE)
18:00–19:00 Treffen AG Planmäßige Professoren der Experimentellen und Klinischen
Pharmakologie und Toxikologie
Location Härtelstraße 16–18 | Rittersaal
13Scientific programme • Tuesday, 3 March
08:30–09:30 Short talks
HS 9 Food Toxicology
08:30 The MDCKII-bABCG2 cell line – assessment of pesticide accumulation in
1 dairy milk
L. Kuhnert, S. Halwachs, W. Honscha (Leipzig/DE)
08:45 Abrogation of heme oxygenase 1 (HO-1) in human colonic epithelial cells
2 potentiates heme iron-triggered ROS formation, DNA damage and cell
death induction
N. Seiwert (Kaiserslautern/DE), S. Wecklein, S. Hasselwander (Mainz/DE)
T. Marschall, T. Schwerdtle (Nuthetal/DE), J. Shay (Dallas/US)
T. Brunner (Konstanz/DE), J. Döhring, P. Steinberg (Hannover/DE)
J. Fahrer (Kaiserslautern, Mainz/DE)
09:00 Detection of DNA adducts of cis- and trans-anethole in primary rat
3 hepatocytes and HepG2 cells
J. A. Fuhlbrueck, C. Rech, E. Richling, A. T. Cartus (Kaiserslautern/DE)
09:15 Pyrrolizidine alkaloid-induced changes in transcription patterns in rat liver
4 and lung
J. Buchmüller, J. Ebmeyer (Berlin/DE), J. Daniel Rasinger (Bergen/NO)
S. Hessel-Pras, A. Braeuning, A. Lampen (Berlin/DE)
09:30–10:30 Short talks
HS 9 Genetic Toxicology
09:30 PARP1 catalytic variants reveal branching and chain length-specific
5 functions of poly(ADP-ribose) in cellular physiology and genotoxic stress
response
L. Rank, A. Krüger, J. Reber, M. Hufnagel, M. Schmalz
I. R. E. A. Trussina, T. Zubel, K. Schütz (Konstanz/DE)
A. Hartwig (Konstanz, Karlsruhe/DE), A. Marx, E. Ferrando-May
A. Bürkle, A. Mangerich (Konstanz/DE)
09:45 B[a]P induced repression of MMR and HR is associated with altered
6 E2F1/E2F4 signaling and represents an early event during DNA
damage-induced senescence
S. Allmann, C. Schwarzenbach, B. Rasenberger, M. Tomicic
M. Christmann (Mainz/DE)
14Scientific programme • Tuesday, 3 March
10:00 Automated screening for oxidative or methylation-induced DNA damage in
61 human cells
M. Mack, K. Schweinlin, N. Mirsberger, A. Bürkle (Konstanz/DE)
10:15 CPI-613 targets mitochondria and synergizes with genotoxic anticancer
8 drugs in colorectal cancer therapy
C. Neitzel, N. Seiwert (Kaiserslautern/DE), S. Stroh, G. Nagel (Mainz/DE)
K. Boengler (Giessen/DE), D. Vogel, M. Huber (Marburg/DE)
A. Moritz (Giessen/DE), M. Linnebacher (Rostock/DE)
J. Fahrer (Kaiserslautern/DE)
09:00–10:30 Short talks
HS 2 Cancer pharmacology and treatment
Chair T. Büch (Leipzig/DE)
09:00 Analysis of clonal evolution to identify potential mechanisms of tyrosine
10 kinase inhibitor resistance in chronic myeloid leukemia cells
M. Kaehler, D. Esser, I. Vater, P. Osteresch, S. Vieth, B. Unger, F. Wiebel
R. Boehm, C. Kaleta (Kiel/DE), O. Ammerpohl (Ulm/DE), I. Cascorbi
I. Nagel (Kiel/DE)
09:15 Functional role of SHP2 in the spontaneous development of resistance to
9 imatinib
P. Osteresch, M. Kaehler, Daniela Esser, I. Vater, F. Wiebel, S. Vieth, C. Kaleta
I. Cascorbi, I. Nagel (Kiel/DE)
09:30 Activation of phospholipase C-γ2 mutants mediating ibrutinib resistance in
11 human chronic lymphocytic leukemia cells by non-catalytic functions of
Bruton´s tyrosine kinase
M. Wist, J. Haas, L. Meier (Ulm/DE), O. Gutman (Tel Aviv/IL), S. Endres, R. Rösler
S. Wiese (Ulm/DE), Y. I. Henis (Tel Aviv/IL), P. Gierschik, C. Walliser (Ulm/DE)
09:45 Identification of novel key targets and candidate drugs in oral squamous
12 cell carcinoma
Z. Shi, J. Fu, Y. Tang (Chengdu/CN)
10:00 The E3 ligase TRIM25 negatively interferes with the translation of
13 caspase-2 – therapeutic implications for sensitizing colon carcinoma cells to
intrinsic apoptosis?
U. Nasrullah, K. Haeussler, A.Biyanee, I. Wittig, J. Pfeilschifter
W. Eberhardt (Frankfurt a. M./DE)
15Scientific programme • Tuesday, 3 March
10:15 OCTN2-mediated uptake of L-carnitine – a potential target for treatment of
14 glioblastoma?
M. A. Fink, H.Paland, M. Schnell, S. Herzog, P. Meisel, M. Grube
S. Vogelgesang, K. Weitmann, A. Bialke, S. Marx, W. Hoffmann, B. Rauch
H. Schroeder, M. V. Tzvetkov, S. Bien-Möller (Greifswald/DE)
09:00–10:30 Short talks
HS 4 G protein-coupled receptors
Chair B. Moepps (Ulm/DE), A. Breit (Munich/DE)
09:00 BiasDB – a comprehensive overview on biased GPCR ligands
15 M. Bermudez, C. Omieczynski, T. Ngoc Nguyen, D.Sribar, L. Deng, D. Stepanov
D. Schaller, G. Wolber (Berlin/DE)
09:15 Interaction of the β2-adrenergic receptor with arrestin 3
16 N. Mösslein, M. Bünemann, C. Krasel (Marburg/DE)
09:30 Role of Gαi2 in neutrophil-platelet complex (PNC) migration during cardiac
17 reperfusion injury in mice
L. Beichert, S. Killinger, D. Köhler, P. Rosenberger, S. Beer-Hammer
B. Nürnberg (Tübingen/DE)
09:45 Absence of Gαi2 in brown and white adipocytes impedes diet-induced obesity
18 V. Leiss, (Tübingen/DE), T. Gnad (Bonn/DE), A. Schönsiegel, T. Sartorius
J. Machann, H.-U. Häring (Tübingen/DE), A. Pfeifer (Bonn/DE)
B. Nürnberg (Tübingen/DE)
10:00 Differential interaction of LARG and p115-RhoGEF with G13 subunits
19 F. Redlin, A.-L. Krett, M. Bünemann (Marburg/DE)
10:15 tba
N. N.
09:00–10:30 Short talks
HS 10 Ion channels and membrane transporters
Chair N. Khajavi (Munich/DE)
09:00 Identification of aurintricarboxylic acid as a potent allosteric antagonist of
21 P2X3 receptors
A. Obrecht, A. Kless, J. E. Meents, N. Urban, M. Schaefer (Leipzig/DE)
A. Lampert, G. Schmalzing, R. Hausmann (Aachen/DE)
16Scientific programme • Tuesday, 3 March
09:15 Angiotensin-II-induced pathological cardiac remodeling – ORAI1 in
22 cardiomyocytes as protective agent
J. E. Camacho Londoño, S. Segin, M. Berlin, C. Richter, R. Medert (Heidelberg/DE)
V. Flockerzi (Homburg/DE), P. Worley (Baltimore/US)
M. Freichel (Heidelberg/DE; Baltimore/US)
09:30 Dispensability of all seven TRPC proteins for the acute neurohumoral
23 Ca2+-signaling induced by Angiotensin II in murine cardiac fibroblasts
A. E. Kraft, J. E. Camacho Londoño, A. Marx, A. Schürger
C. Richter (Heidelberg/DE), L. Birnbaumer (Buenos Aires/AR, Durham, NC/US)
A. Dietrich (Munich/DE), M. Freichel (Heidelberg/DE)
09:45 Physiological function of TRPV6 channels during pregnancy
24 M. Winter, P. Weissgerber, C. Fecher-Trost, V. Flockerzi (Homburg/DE)
10:00 Identification of OCaR1 as a gatekeeper of lysosomal-granular Ca2+ release
25 and regulated exocytosis
V. Tsvilovskyy, U. Kriebs, A. Bach (Heidelberg/DE), A. Jha (Bethesda, MD/US)
A. Wirth (Heidelberg/DE), C. Grimm (Munich/DE), U. Wissenbach (Homburg/DE)
K. Zimmermann (Bonn/DE), P. Weissgerber (Homburg/DE), D. Vogt
D.Schumacher, J. Camacho Londoño (Heidelberg/DE), C. Wahl-Schott (Munich/DE)
A. Pfeifer (Bonn/DE), M. Biel (Munich/DE), P. Lipp, V. Flockerzi (Homburg/DE)
S. l. Muallem (Bethesda, MD/US), M. Freichel (Heidelberg/DE)
10:15 Agonist-dependent switching of ion selectivity in a lysosomal ion channel
26 Y.-K. Chao, S. Gerndt, C.-C. Chen (Munich/DE), Y. Yuan (London/GB)
A. Scotto Rosato, E. Krogsaeter (Munich/DE), N. Urban (Leipzig/DE)
O. N. P. Nguyen, M. Keller, A. M. Vollmar, T. Gudermann
J. Schredelseker (Munich/DE), M. Schaefer (Leipzig/DE), M. Biel (Munich/DE)
C. Wahl-Schott (Hannover/DE), F. Bracher (Munich/DE), S. Patel (London/GB)
C. Grimm (Munich/DE)
10:45–11:00 Opening ceremony
HS 9 Welcome note by the conference chairs
M. Schaefer, A. Aigner, A. Richter (Leipzig/DE), H. Barth (Ulm/DE)
11:00–11:45 Plenary lecture I – Pharmacology
HS 9
Chair M. Schaefer (Leipzig/DE)
11:00 Cellular therapeutics – CAR-T cells and beyond
U. Köhl (Leipzig/DE)
17Scientific programme • Tuesday, 3 March
12:00–13:30 Symposium 1
HS 9 New therapeutic trends
Chairs J. Stingl (Aachen/DE), P. Most (Heidelberg/DE)
12:00 Novel targets for heart failure therapy
P. Most (Heidelberg/DE)
12:30 Novel approaches of antibody-based immunotherapy
C. Kellner (Munich/DE)
13:00 Regulation of ATMPs – novel trends
R. Sanzenbacher (Langen/DE)
12:00–13:30 Forum Young Scientists
HS 2 Photopharmacology and optogenetics – switching on the light in therapy
Chairs C. Klenk (Zurich/CH), A. Ahles (Munich/DE)
12:00 Photopharmacology of G-protein coupled receptors
R. Leurs (Amsterdam/NL)
12:22 Photopharmacology to control the cytoskeleton
O. Thorn-Seshold (Munich/DE)
12:44 The adhesion-GPCR CIRL promotes mechanosensory signal discrimination
R. J. Kittel (Leipzig/DE)
13:06 Optogenetics to enlighten G protein signalling in the heart
T. Brügmann (Göttingen/DE)
12:00–13:30 Symposium 2
HS 4 Adenine nucleotides in immunity and inflammation
Chairs A. Guse (Hamburg/DE), A. Pfeifer (Bonn/DE)
12:00 Tools and drugs for purinergic targets – important players in inflammation
and immunity
C. Müller (Bonn/DE)
12:27 Initial calcium microdomains in T cells
B.-P. Diercks (Hamburg/DE)
12:54 Neuromodulation by adenosine in health and disease
D. Hirnet (Hamburg/DE)
13:11 Nanobodies as modulators of purinergic signalling
B. Rissiek (Hamburg/DE)
18Scientific programme • Tuesday, 3 March
12:00–13:30 Symposium 3
HS 10 Air pollution related chronic inflammatory diseases – from molecular
mechanism to disease control
Chairs M. Schmidt (Groningen/NL), H. Barth (Ulm/DE)
12:00 In vitro models to study pulmonary diseases
M. Frick (Ulm/DE)
12:22 Targeted modulation of monocyte/macrophages in intensive care unit
models
H. Barth (Ulm/DE)
12:44 Effects of traffic related air pollution on mouse lung and brain
R. Schins (Düsseldorf/DE)
13:06 Air pollution and its impact on the lung-brain axis
M. Schmidt (Groningen/NL)
12:00–13:30 Symposium 4
HS 15 Microbiota and toxicology – links and questions
Chairs C. Esser, K. Hochrath (Düsseldorf/DE)
12:00 Role of microbiota in chemical toxicity
S. Sturla (Zurich/CH)
12:30 Dietary heme iron, microbiota and intestinal carcinogenesis
J. Fahrer (Kaiserslautern/DE)
13:00 Coal tar and the skin microbiome
E. van den Bogaard (Nijmegen/NL)
13:30–14:15 Get-together
Location Foyer (see page 71)
14:30–16:00 Symposium 5
HS 10 Mechanisms of chemosensation – SFB-TRR 152
Chair T. Gudermann (Munich/DE)
14:30 Chemosensation in olfactory organs
F. Zufall (Homburg/DE)
15:00 Deciphering molecular mechanisms of irritant sensing
S.-E. Jordt (New York, NY/US)
19Scientific programme • Tuesday, 3 March
15:30 Pulmonary effects of alkylating agents
D. Steinritz (Munich/DE)
15:45 Chemosensation via TRPA1 – possible roles in mediating adverse effects of drugs
M. Schaefer (Leipzig/DE)
15:15–16:00 Meet the company
HS 2 (see page 88)
Chair K. Bestehorn (Zell/DE)
16:15–17:45 Symposium 6
HS 9 Stratified pharmacotherapies in oncology
Chairs J. Wolf, U. Fuhr (Cologne/DE)
16:15 NSCLC – non small cell lung cancer
J. Wolf (Cologne/DE)
16:45 Malignant melanoma
M. Ziemer (Leipzig/DE)
17:15 Chronic myeloid leukemia – mechanisms of resistance
M. Kähler (Kiel/DE)
16:15–17:45 Symposium 7
HS 2 Existence and relevance of thresholds of genotoxic carcinogens
Chairs M. Esselen (Münster/DE), A. Cartus (Kaiserslautern/DE)
16:15 Approaches for risk assessment of genotoxic carcinogens
A. Hartwig (Karlsruhe/DE)
16:45 Threshold vs. cut-off – impact of genotoxicity testing for pesticide risk
assessment
K. Meurer (Ludwigshafen/DE)
17:15 Deriving occupational exposure limits for natural substances
A. Thiel (Kaiseraugst/CH)
16:15–17:45 Symposium 8
HS 4 Structural dynamics of G protein-coupled receptors
Chairs A. Beck-Sickinger, T. Schöneberg (Leipzig/DE)
16:15 Activation of adhesion GPCRS
T. Schöneberg (Leipzig/DE)
20Scientific programme • Tuesday, 3 March
16:37 Mechanical force sensing through adhesion-type G protein-coupled receptors
T. Langenhahn (Leipzig/DE)
16:59 Allosteric modulators of the pancreatic polypeptide receptor
A. Beck-Sickinger (Leipzig/DE)
17:22 It is high-time for GPCR structure-based drug discovery
J. Meiler (Leipzig/DE)
16:15–17:45 Symposium 9
HS 10 Antiobesic drug – new hopes or riding a dead horse?
Chairs M. Blüher (Leipzig/DE), M. Kleinert (Munich/DE)
16:15 Obesity is a disease!
M. Blüher (Leipzig/DE)
16:37 Multivalent peptide agonists to treat obesity
M. Kleinert (Munich/DE)
17:00 Consequences of obesity on the vasculature
S. Steiner (Leipzig/DE)
17:23 Novel pharmacological strategies for lipid disorders
U. Laufs (Leipzig/DE)
18:00–19:30 General meeting
HS 9 Gesellschaft für Toxikologie (GT)
18:00–19:30 General meeting
HS 2 Deutsche Gesellschaft für Pharmakologie (DGP)
18:00–19:00 General meeting
HS 4 Deutsche Gesellschaft für Klinische Pharmakologie und Therapie
(DGKliPha)
19:30–20:15 Social evening Forum Young Scientists – Science slam
Location Beyerhaus Leipzig (see page 71)
21Scientific programme • Wednesday, 4 March
08:30–09:30 Short talks
HS 9 Toxic compounds
Chair A. Braeuning (Berlin/DE)
08:30 Reduced wound healing ability of mesenchymal stem cells in chronic
27 senescence after sulfur mustard exposure
S. Rothmiller, N. Jäger (Munich/DE), A. Bürkle (Konstanz/DE), D. Steinritz
H. Thiermann, A. Schmidt (Munich/DE)
08:45 The pyrrolizidine alkaloid senecionine destroys metabolism-dependent
28 hepatic sinusoidal cells and induces cholestasis in vivo
S. Hessel-Pras, A. Braeuning, (Berlin/DE), G. Guenther, A. Adawy (Dortmund/DE)
A.-M. Enge, J. Ebmeyer (Berlin/DE), C. J. Henderson (Dundee/GB)
J. G. Hengstler (Dortmund/DE), A. Lampen (Berlin/DE), R. Reif (Dortmund/DE)
09:00 Carbon monoxide – a novel stress response mediator?
29 D. Stucki, J. Steinhausen, D. Brilhaus, P. Westhoff, A. P. M. Weber
W. Stahl (Düsseldorf/DE)
09:15 Consequences of manganese overload in C. elegans – oxidative stress and
30 DNA damage
M. M. Nicolai (Wuppertal/DE), J. Baesler(Berlin/DE), M. Aschner (Bronx NY/US)
T. Schwerdtle (Potsdam/DE), J. Bornhorst (Wuppertal/DE)
09:30–10:30 Short talks
HS 9 Toxins
Chair R. Gerhard (Hannover/DE)
09:30 A hidden treasure – discovery of an endogenous inhibitor against
31 Clostridium botulinum C2 toxin from human hemofiltrate peptide library
S. Fischer, P. Gauckler, L. Staendker, A. Rodriguez-Alfonso (Ulm/DE)
W.-G. Forssmann (Hannover/DE), H. Barth (Ulm/DE)
09:45 Eschericia coli subtilase cytotoxin enters human cells without a transport subunit
32 K. Sessler, P. Papatheodorou, F. Weiß, J. Michaelis (Ulm/DE)
M. Krause (Hohenheim/DE), H. Schmidt (Hohenheim/DE), H. Barth (Ulm/DE)
10:00 The transporter molecule PA63 from Bacillus anthracis delivers the tumor
33 metastasis suppressor protein NDPK-A/NME1 into human breast cancer cells
I. Felix, H. Barth (Ulm/DE), T. Wieland (Mannheim/DE)
22Scientific programme • Wednesday, 4 March
10:15 Human motor neurons differentiated from pluripotent stem cells as
34 superior target cells for botulinum neurotoxin potency testing
M. Schenke (Hannover/DE), B.-M. Schjeide, G. P. Püschel (Nuthetal/DE)
B. Seeger (Hannover/DE)
09:00–10:30 Short talks
HS 2 Disease models and drug development I
Chair U. Storch (Munich/DE)
09:00 Generation of malignant transformed monoclonal cell lines for metabolic
35 cancer research
F. Meyer, R. Thierbach (Jena/DE)
09:15 The human engineered connective tissue model – a versatile tool for
36 understanding cardiac fibroblast behavior and drug testing
G. L. Santos, F. Meyer, A. DeGrave, H. Schröder, T. Meyer, W.-H. Zimmermann
S. Lutz (Göttingen/DE)
09:30 Neonatal seizures and long-term consequences in a novel rat model of birth
37 asphyxia respond to treatment with midazolam
B. Gailus, W. Löscher (Hannover/DE)
09:45 Mechanism of artemisinin activation in Leishmania tarentolae and its link to
38 heme degradation
L. Gille, G. Geroldinger, M. Tonner, J. Quirgst, M. Walter (Vienna/AT)
S. De Sarkar (Kolkata/IN), L. Monzote (Havana/CU), K. Stolze, J. C. Duvigneau
K. Staniek (Vienna/AT), M. Chatterjee (Kolkata/IN)
10:00 New OCaR2 proteins at lysosomal-SR junction controls cardiomyocyte-Ca2+
39 signaling, pathological remodeling including transcriptome profile and
determine fatal ventricular arrhythmias
J. E. Camacho Londoño, M. Berlin, S. Meyer, C. Hofmann
V. Kuryshev (Heidelberg/DE), S. Gerndt (Munich/DE), R. Ottenheijm, A. Wirth
L. Bacmeister, U. Kriebs (Heidelberg/DE), V. Flockerzi (Homburg/DE), M. Völkers
F. Leuschner (Heidelberg/DE), C. Wahl-Schott (Hannover/DE), M. Biel, F. Bracher
C. M. Grimm (Munich/DE), C. Dieterich, M. Freichel (Heidelberg/DE)
10:15 iPSC modelling of a novel patient-specific compound heterozygous titin
83 mutation causing cardiomyopathy
M. Poetsch (Dresden/DE), J. Qi (Göttingen/DE), C. Mehnert (Dresden/DE)
M. Gautel (London/GB), K. Guan (Dresden/DE)
23Scientific programme • Wednesday, 4 March
09:00–10:30 Short talks
HS 4 Cardiac pharmacology and treatment I
Chair V. Leiss (Tübingen/DE)
09:00 Stabilization of HIF-1 signalling protects from reoxygenation injury in
41 engineered human myocardium
E. Levent, C. Noack, L. Zelarayan, D. Katschinski, W.-H. Zimmermann
M. Tiburcy (Göttingen/DE)
09:15 A novel hypoxia-reoxygenation model to study the protective effect of
42 hypoxia or opioid preconditioning using cardiac tissue engineering and
induced pluripotent stem cell technology
S. Funcke (Hamburg/DE), T. Werner (Brisbane/AU, Hamburg/DE)
M. Hein (Aachen/DE), B. Ulmer, A. Hansen, T. Eschenhagen
M. Hirt (Hamburg/DE)
09:30 MiR-21 in cardiac macrophages regulates cardiac remodelling
43 D. P. Ramanujam, A. P. Schön, C. Beck, G. Felician, A. Dueck
S. Engelhardt (Munich/DE)
09:45 Protective effects of Gαi3-deficiency in a mouse model of β1-adrenoceptor
44 mediated cardiomyopathy
T. Schröper, D. Mehrkens (Cologne/DE), V. Leiss (Tübingen/DE)
S. Engelhardt (Munich/DE), S. Herzig (Köln/DE)
L. Birnbaumer (Research Triangle Park/DE), B. Nürnberg (Tübingen/DE)
J. Matthes (Cologne/DE)
10:00 The LXR Agonist AZ876 attenuates cardiac damage in an isoproterenol
45 induced cardiomyopathy model
D. Ritter, C. Jaeger, R. Klopfleisch, A. Foryst-Ludwig, U. Kintscher (Berlin/DE)
10:15 Protease-activated receptor PAR4 drives cardiac inflammation in diabetes
46 A. Fender, S. Stolte, K. Leineweber, M. Kamler, D. Dobrev (Essen/DE)
09:00–10:30 Short talks
HS 10 Signal transduction and second messengers
Chair S. Lutz (Göttingen/DE)
09:00 The role of semaphorins in the intestinal epithelium
47 F. Hub (Marburg/DE), M. Looso (Bad Nauheim/DE), M. Mazzola (Boston/US)
I. Shcheglova, H.-J. Gröne (Marburg/DE), T. Worzfeld (Marburg, Bad Nauheim/DE)
24Scientific programme • Wednesday, 4 March
09:15 Plexin signaling controls epidermal stem cell fate in mammalian epidermis
48 during development and cancer
C. Jiang, L. Kaiser, L. Zhou, D. Brandt, D. Zhao (Marburg/DE)
T. Worzfeld (Bad Nauheim, Marburg/DE)
09:30 Impact of NO-GC1 on Ang II-induced cardiac hypertrophy and vascular
49 remodelling
K. Broekmans, M. Russwurm, D. Koesling, E. Mergia (Bochum/DE)
09:45 A cardio-safe peptide-based targeting strategy protects from pathological
50 ERK1/2 signalling
T. Brand, C. Schanbacher, A. Tomasovic, S. Kramer, M. Hümmert (Würzburg/DE)
O. Müller (Kiel/DE), D. Dobrev (Essen/DE), A. El-Armouche (Dresden/DE)
F. Cuello (Hamburg/DE), K. Lorenz (Würzburg/DE)
10:00 Optical mapping reveals that spatiotemporal cAMP signaling is controlled
52 by attoliter-sized compartments
A. Bock, P. Annibale, C. Konrad, S. Anton, M. J. Lohse (Berlin/DE)
S. Sivaramakrishnan (Minneapolis/US), I. Maiellaro (Würzburg/DE)
M. J. Lohse (Berlin/DE)
10:15 Genetically-encoded FRET-based biosensors to monitor cAMP dynamics in
51 nanodomains
R. Thomas, C. Konrad, S. Anton, M. J. Lohse, A. Bock (Berlin/DE)
09:00–10:30 AGAH Workshop – introduction to physiologically-based pharmacokinetic
HS 15 (PBPK) modeling and the Open Systems Pharmacology (OSP Suite)
(PK-Sim® & MoBi®) I
Chairs A. Kovar (Frankfurt a. M./DE), T. Lehr (Saarbrücken/DE)
09:00 Introduction to PBPK modeling and quantitative systems pharmacology (QSP)
J. Schlender (Leverkusen/DE)
09:45 PBPK predictions for FIH using PK-SIM: A case study
D. Teutonico (Paris/FRA)
11:00–12:30 Symposium 10
HS9 Paul-Martini-Symposium – Modellierungen und Simulationen in Hinblick
auf Wirksamkeit und Sicherheit von Arzneimitteltherapien
Chairs K. Diefenbach (Berlin/DE), K. Bestehorn (Zell/DE)
11:00 Modell-basiertes Management von drug drug interactions und anderen
klinisch relevanten Kovariaten
S. Frechen (Leverkusen/DE)
25Scientific programme • Wednesday, 4 March
11:22 Data Science und mathematische Modelle zur Optimierung der
Arzneimittelentwicklung
P. Nörtersheuser (Ludwigshafen/DE)
11:44 Modellbasierte Entscheidungsfindung im klinischen Alltag
T. Lehr (Saarbrücken/DE)
12:06 Modell- und Physiologie-basierte Toxikokinetik von Aluminium als Adjuvans
in Arzneimitteln
G. Wangorsch (Langen/DE)
12:40–14:10 Workshop – Was bedeutet der NKLM2 für die Pharmakologie/Toxikologie?
HS 10
Chairs R. Seifert (Hannover/DE), R. Maas (Erlangen/DE)
12:40 Die Implementierung pharmakologischer Inhalte in den NKLM2 und GK2 Medizin
R. Seifert (Hannover/DE)
13:10 Die Sicht der Klinischen Pharmakologie
R. Maas (Erlangen/DE)
13:40 Die Sicht der Toxikologie
I. Just (Hannover/DE)
12:40–17:40 AGAH Workshop – introduction to physiologically-based pharmacokinetic
HS 15 (PBPK) modeling and the Open Systems Pharmacology (OSP Suite)
(PK-Sim® & MoBi®) II
Chairs A. Kovar (Frankfurt a. M./DE), T. Lehr (Saarbrücken/DE)
12:40 PBPK modeling in pediatric and geriatric populations
J. Schlender (Leverkusen/DE)
13:25 PBPK modeling in renally impaired patients
N. Hanke (Saarbrücken/DE)
14:10 Break
14:25 Assessment and prediction of drug drug interactions utilizing PBPK modeling
S. Frechen (Leverkusen/DE)
15:10 Modeling of glucose homeostasis in the diabetes QSP plattform
S. Schaller (Saterland/DE)
26Scientific programme • Wednesday, 4 March
15:55 Break
16:10 Drug delivery via skin – implications for PBPK modelling
D. Selzer (Saarbrücken/DE)
16:55 Application of PBPK modeling for forensic assessments
T. Lehr (Saarbrücken/DE)
14:45–16:15 Young Scientists – award selection talks
HS 9
14:45 Rasal1 – the missing GAP downstream of plexins
55 C. Höß, D. Brandt, H.-J. Gröne (Marburg/DE), R. Xu
T. Worzfeld (Marburg, Bad Nauheim/DE), J. M. Swiercz, R. Lu
S. Offermanns (Bad Nauheim/DE), N. Petersen (Copenhagen/DK)
15:00 Targeting phosphodiesterase 2 – an innovative strategy to protect against
56 cardiac arrhythmia
M. Fahmi, M. Günscht, J. Siegert, F. Dutt, K. Richter, M. Wagner, A. El-Armouche
S. Kämmerer (Dresden/DE), N. Dybkova (Göttingen/DE)
S. Sossalla (Göttingen, Regensburg/DE)
15:15 Novel effects of the helix loop helix factor Id3 on hyaluronan-rich matrix
57 in adipose tissue
A. Misiou, J. Fischer, M. Grandoch (Düsseldorf/DE), D. Harmon, J. Hensien
J. Garmey, C. McSkimming, V. Osinski, M. Marshall
C. McNamara (Charlottesville, Va/US)
15:30 The insulin-like growth factor binding protein 5 (IGFBP5) in the transition to
58 heart failure
M. Jassyk, C. Rocha, M. Woelfer, S. Khadjeh, L. M. Iyer, M. Tiburcy
M. Patapia Zafeiriou, G. Hasenfuss, K. Toischer, L. C. Zelarayan (Göttingen/DE)
O. Müller (Hamburg, Kiel/DE)
15:45 Mixture effects on toxicologically relevant liver proteins after pesticide
53 treatment in HepaRG cells
F. Schmidt, A. Steinhilber, T. Joos, O. Pötz (Reutlingen/DE), A. Mentz
J. Kalinowski (Bielefeld/DE), D. Lichtenstein, A. Braeuning (Berlin/DE)
16:00 Bacterial exotoxin-based biohybrid transporters for delivery of therapeutic
54 peptides into the cytosol or across the blood-brain barrier
M. Fellermann, F. Wondany, R. Noschka, S. Carle, S. Stenger, J. Michaelis
H. Barth (Ulm/DE)
27Scientific programme • Wednesday, 4 March
14:45–16:15 Symposium 11
HS 2 Nanomedicine and theranostics
Chairs A. Aigner (Leipzig/DE), T. Lammers (Aachen/DE)
14:45 Theranostic nanomedicine
T. Lammers (Aachen/DE)
15:15 Biomedical applications of iron oxide nanoparticles – the SEON concept
C. Alexiou (Erlangen/DE)
15:45 Bacterial nanocellulose – pharmacological insights in the application of a
natural polymer
D. Fischer (Jena/DE)
14:45–16:15 Symposium 12
HS 4 ADME research and PGx
Chairs I. Cascorbi (Kiel/DE), M. Schwab (Stuttgart/DE)
14:45 Impact of ABC transporters in Alzheimer’s disease
J. Pahnke (Oslo, Norway)
15:15 Use of organoids for ADME research
M. Schwab (Stuttgart/DE)
15:45 Impact of ABC transporters in Alzheimer’s disease in clinical routine
R. van Schaik (Rotterdam/NL)
14:45–16:15 Symposium 13
HS 10 Novel aspects of bacterial toxins – Joint symposium SFET/GT
Chairs K. Ernst (Ulm/DE), M.-R. Popoff (Paris/FR)
14:45 Pertussis toxin
K. Ernst (Ulm/DE)
15:07 Clostridium difficile toxins
R. Gerhard (Hannover/DE)
15:29 Clostridial toxins
M.-R. Popoff (Paris/FR)
15:51 Bordetella pertussis toxins
D. Ladant (Paris/FR)
28Scientific programme • Wednesday, 4 March
16:30–17:15 Plenary lecture II – Clinical Pharmacology
HS 9
Chair I. Cascorbi (Kiel/DE)
16:30 Tumor immunology from bench to bedside and back – rationale for T cell
deinhibition for cancer therapy
S. Kobold (Munich/DE)
17:30–18:30 Short talks – in vitro toxicology I
HS 9
Chair N. Schupp (Düsseldorf/DE)
17:30 Microphysiometry-based prediction models from cell suspensions to 3D
59 tissue constructs
J. Wiest (Kronburg/DE)
17:45 Prediction of human drug‑induced liver injury (DILI) in relation to oral doses
60 and blood concentrations
W. Albrecht, F. Kappenberg, T. Brecklinghaus, K. Edlund (Dortmund/DE)
I. Gardner (Sheffield/GB), J. Rahnenführer, J. G. Hengstler (Dortmund/DE)
18:00 Direct detection of mutations arising at a damage site in DNA
7 M. Rodriguez-Alvarez, L. Sarmini, D. Kim, A. Khobta (Mainz/DE)
18:15 HepaChip-MWP – an organ-like perfusable cell culture system in
62 multiwell plate format for toxicity testing
M. Busche, S. Werner, B. Hagmeyer, M. Pawlak (Reutlingen/DE), H. Becker
J. Schnabel (Jena/DE), K. Gall, R. Hemmler (Osnabrück/DE), G. Damm (Leipzig/DE)
S. Beuck, T. Klaassen (Bergheim/DE), J. Moer, A. Ullrich (Schwerin/DE)
M. Matz-Soja, R. Gebhardt (Leipzig/DE), M. Stelzle (Reutlingen/DE)
17:30–18:30 Short talks – CNS/endocrine pharmacology and treatment
HS 2
Chair F. Richter Assencio (Hannover/DE)
17:30 Mental effects of analgesic drugs – review of literature data and concept for
63 a placebo-controlled clinical trial
A. Sachkova, J. Brockmöller, T. Prukop, J. Stingl (Göttingen/DE)
29Scientific programme • Wednesday, 4 March
17:45 Limited association between 5-HT receptor gene polymorphisms and treatment
64 response in antidepressant treatment-free patients with depression
T. Ochi (Groningen/NL), N. Vyalova, I. Losenkov, D. Paderina
I. Pozhidaev (Tomsk/RU), A. Loonen (Groningen, Halsteren/NL), G. Simutkin
N. Bokhan, S. Ivanova (Tomsk/RU), B. Wilffert (Groningen/NL)
18:00 Endogenous brain endothelial thrombomodulin protects the ischemic brain
65 by affecting capillary diameter and vessel proliferation
J. Wenzel, J. Assmann, M. Khan, M. Schwaninger (Lübeck/DE)
18:15 Telmisartan induces a specific signature of gut microbiota, which may
66 participate to its anti-obese potency
L. Beckmann, A. Künstner, I. Stölting, S. Ibrahim, M. Freitag
E. Langan, J. Knobloch, W. Raasch (Lübeck/DE)
17:30–18:30 Short talks – Cardiac pharmacology and treatment II
HS 4
Chairs S. Kämmerer (Dresden/DE), A. Ahles (Munich/DE)
17:30 Novel mitochondrial Ca2+ enhancers for the treatment of cardiac arrhythmia
67 P. Sander, D. Arduino, F. Wilting, M. Schweitzer, T. Gudermann, F. Perocchi
J. Schredelseker (Munich/DE)
17:45 Inactivation of HDAC2 attenuates atrial structural and functional
68 remodeling in CREM-IbΔC-X transgenic mice, a mouse model of
spontaneous onset atrial fibrillation
J. S. Schulte, J. P. Reinhardt, S. Hamer, B. Scholz, M. D. Seidl
F. U. Müller (Münster/DE)
18:00 Profound differences in transcriptomics between reticulated and
69 non-reticulated platelets from healthy donors, CCS and STEMI patients by
next generation sequencing (NGS)
L. Hille, T. Nührenberg, L. Hein, F.-J. Neumann, D. Trenk (Bad Krozingen/DE)
18:15 Role of B lymphocytes in regulating vascular function
70 N. Xia, S. Hasselwander, R. Schüler, S. Karbach, P. Wenzel, A. Daiber, T. Münzel
N. Hövelmeyer, A. Waisman, H. Li (Mainz/DE)
30Scientific programme • Wednesday, 4 March
17:30–18:30 Short talks – Nuclear receptors, enzymes and other targets
HS 10
Chair H. Bruckmüller (Kiel/DE)
17:30 Degron-mediated depletion reveals NCBP1 as a multimodal executer of
71 cytokine functions
J. Meier-Sölch, D. Newel, H. Weiser, N. Biber, U. Tenekeci
M. Kracht (Giessen/DE)
17:45 Role of the pyridoxal phosphatase PDXP in red blood cell vitamin B6
72 metabolism
E. Jeanclos, L. Witzinger, A. Keller, A. Gohla (Würzburg/DE)
18:00 Ligand-specific regulation of non-canonical aryl hydrocarbon receptor
73 signaling and its impact on prostaglandin D2 metabolism
C. Vogeley (Düsseldorf/DE), M. Nakamura (Düsseldorf/DE, Nagoya/JP), S. Maaß
M.Pollet (Düsseldorf/DE), C. F. A. Vogel (Davis/US), J. Krutmann
C. Esser (Düsseldorf/DE), D. Lang (Wuppertal/DE)
T. Haarmann-Stemmann (Düsseldorf/DE)
18:15 Triarylmethane class of compounds as potential modulators of the aryl
74 hydrocarbon receptor (AhR) – synthesis and in vitro evaluation
E. Goya-Jorge (València/ES), R. Gozalbes, S. J.Barigye (València/ES)
M. Sylla-Iyarreta Veitía (Paris/FR), R. M. Giner (València/ES)
18:30–19:30 Award ceremony
HS 9
20:00–23:15 Social evening – Ratskeller
Location Ratskeller Leipzig (see page 71)
31Scientific programme • thursday, 5 March
08:30–09:30 Short talks – in vitro toxicology II
HS 9
Chair L. T. Anger (San Francisco, CA/US)
08:30 Chemotaxis of polarized macrophages induced by nanoparticles – a model
75 for the differentiation of local and systemic biological effects
N. Kaiser, N. Rosenkranz, C. Monsé, D. Weber, G. Johnen, A. Brik, T. Brüning
J. Bünger, G. Westphal (Bochum/DE)
08:45 Structural alerts for predicting skin sensitization – in silico model derived
79 from a data set of 1982 organic compounds
G. Schüürmann (Leipzig/DE), M. Hillebrand (Dessau-Roßlau/DE), R. Kühne
R.-U. Ebert (Leipzig/DE)
09:00 Adherens junction reorganization as endpoint to identify estrogenic substances
77 M. Kornhuber, S. Klutzny, S. Dunst, M. Oelgeschläger, G. Schönfelder (Berlin/DE)
09:15 QSAR and read across for the evaluation of the genotoxic potential of plant
78 protection residues – an industry perspective
M. Frericks, D. Urbisch (Limburgerhof/DE), F. Kluxen (Cologne/DE)
A. Patel (Rochelle/US), A. Lee (Midland/US), M. Corvaro, J. Zhang
E. Shipp (Wilmington/US), S. Wijesalere (Rochelle/US), L. Brierley
A. Booth (Basel/CH), A. Hueser (Wilmington/US; Monheim/DE)
09:30–10:30 Short talks – in vitro toxicology III
HS 9
Chair A. Mangerich (Konstanz/DE)
09:30 In vitro metabolome and biochemical pathway analysis of nephrotoxicants
76 in NRK-52E cells
B. Birk, S. Sperber, S. Wallisch (Ludwigshafen/DE), M. Herold
V. Haake (Berlin/DE), M. Amma (Ludwigshafen/DE), T. Walk (Berlin/DE)
H. Kamp, B. van Ravenzwaay (Ludwigshafen/DE)
09:45 Uptake and transport of hepatotoxic pyrrolizidine alkaloids in HepaRG cells
80 A.-M. Enge, J. Waizenegger (Berlin/DE), H. Hammer, O. Pötz (Reutlingen/DE)
F. Kaltner, C. Gottschalk (Munich/DE), A. Lampen, A. Braeuning
S. Hessel-Pras (Berlin/DE)
10:00 In vitro and in vivo (geno)toxicity testing of industrially relevant quartz
81 species, covalently surface-modified to reduce lung toxicity
C. Ziemann (Hannover/DE), E. Monfort, M. J. Ibáñez, A. López-Lilao (Castellón/ES)
G. Bonvicini (Bologna/IT), O. Creutzenberg (Hannover/DE)
32Scientific programme • thursday, 5 March
10:15 Responses of human monocyte-derived macrophages and differentiated
82 THP-1 cells exposed to silica and copper oxide particles
J. Lichter, K. Hertz (Trier/DE), P. Schumacher, A. Hartwig (Karlsruhe/DE), U. Bock
B. Blömeke (Trier/DE)
09:00–10:30 Short talks – Disease models, drug development II
HS 2
Chair B. Renner (Dresden/DE)
09:00 Investigating calcium channels modulation of a novel phenylethylamine
40 compound in Caenorhabditis elegans
Y.-Y. Mak, F.-K. Lee, K.-H. Lim, C. Kong (Semenyih/MY), Y. Mbaki (Nottingham/GB)
S.-M. Then, K.-N. Ting (Semenyih/MY)
09:15 Vioprolide A impairs angiogenic processes in human endothelial cells
84 in vitro – inhibition of protein translation as central mechanism?
L. D. Burgers, B. Luong (Frankfurt/DE), S. Zahler (Munich/DE)
R. Müller (Saarbrücken/DE), R. Fürst (Frankfurt/DE)
09:30 Adipose tissue – heart crosstalk – pharmacological inhibition of non-cardiac
85 ATGL by atglistatin improves myocardial stiffness in a murine model of
cardiac fibrosis
A. Thiele, N. Beyhoff, A. Blumrich, D. Ritter, R. Klopfleisch, J. Grune, E. Smeir
K. Lüttges (Berlin/DE), R. Zechner, R. Breinbauer (Graz/AT), U. Kintscher
A. Foryst-Ludwig (Berlin/DE)
09:45 Protective effects of wheat germ oil against erectile and endothelial
86 dysfunction in streptozotocin-induced diabetic rats
H. Guven (Istanbul/TR), N. Durmus, N. Hocaoglu, O. Guner, S. Acar, P. Akan
O. Gursoy Calan (Izmir/TR)
10:00 Pharmacological targeting of phosphoglycolate phosphatase
87 A. Gohla, E. Jeanclos, J. Schloetzer (Würzburg/DE), J. P. von Kries (Berlin/DE)
H. Schindelin (Würzburg/DE)
10:15 The small GTPase Rab27a contributes to the processing of pain
88 T. Groß, G. Wack, K. Syhr(Frankfurt/DE), T. Tolmachova (London/GB)
M. C. Seabra (Lisbon/PT), A. Schmidtko (Frankfurt a. Main/DE)
W. Kallenborn-Gerhardt (Frankfurt a. Main/DE)
33Scientific programme • thursday, 5 March
09:00–10:30 Short talks – Immunopharmacolgy/inflammation/antiinfectives
HS 4
Chair H. Mühl (Frankfurt a. M./DE)
09:00 Investigation of protein protein interactions of the P2X7 > receptor by
89 cross-linking mass spectrometry
R. Kopp (Munich/DE), S. Chaturvedi (Lucknow/IN), V. Agarwal
N. Prasad (Lucknow/IN)
09:15 Generation and activation of myeloid derived suppressor cells using
90 prostaglandin E2 and EP receptor agonists in a murine model of asthma
C. van Geffen, S. Kolahian (Tübingen/DE)
09:30 Rapamycin prolongs skin allograft survival in obese mice through
91 myeloid-derived suppressor cells
A. Deißler, A. Della Penna, C. van Geffen, B. Nürnberg, A. Königsrainer
M. Quante, S. Kolahian (Tübingen/DE)
09:45 Hepatic transcriptome analyis for identification of novel factors
92 determining experimental paracetamol-induced liver injury
S. Gonther, M. Bachmann, I. Goren, J. Pfeilschifter, H. Mühl (Frankfurt a. M./DE)
10:00 Lipopolysaccharide reduces urethral smooth muscle contractility
93 independently of TLR4 activation – implication of caspase-1 and
cyclooxygenase activation
F. Beraldi Calmasini, E. Costa Alexandre, M. Gonçalves Oliveira
F. H. da Silva (Campinas/BR), A. G. Soares, S. K. Pereira Costa (São Paulo/BR)
E. Antunes (Campinas/BR)
10:15 Preliminary results from systematic review and meta-analysis on psychiatric
94 adverse events in tenofovir-based HIV-medication and prophylaxis
M. S. Schaefer, L. E. Villagomez Fuentes, K. Allers, T. Schneider, R. Kreutz
T. G. Riemer (Berlin/DE)
09:00–10:30 Short talks – Drug transport, pharmacokinetics and PK/PD modeling
HS 10
Chairs R. Böhm (Kiel/DE), D. Ramanujam (Munich/DE)
09:00 Evaluation of dosing strategies for the oral one-compartment model to
95 reach the therapeutic window following multiple oral drug administration
A. Ring (Bloemfontein/ZA), M. Juma (M’Bour/SN)
09:15 Evaluating uncertainty and variability in quantitative in vitro to in vivo
96 extrapolation approach – empirical PBTK model versus physiological 26
compartment PBTK model
E. Fabian, P. Kalra, B. van Ravenzwaay, R. Landsiedel (Ludwigshafen/DE)
34Scientific programme • thursday, 5 March
09:30 A whole body pharmacokinetics model based on residence time theory,
97 implemented in Python
A. Ring (Bloemfontein/ZA), L. Frenzel (Wedel/DE)
09:45 Pharmacogenomics analysis of the pharmacokinetics and
98 pharmacodynamics of loop diuretic drugs
C. Dücker, S. V. Vormfelde (Göttingen/DE), E. Schäffeler (Stuttgart/DE)
M. Schwab (Stuttgart, Tübingen/DE), J. Brockmöller (Göttingen/DE)
10:00 Development and pharmacokinetic assessment of tetrahydrocurcumin
99 solid lipid nanoparticles
H. R. Shiek Abdul Kadhar Mohamed Ebrahim (Kuala Lumpur/MY)
T. T. Chungath (Ernakulam/IN), H. Ranganathan, S. Muthusamy (Coimbatore/IN)
10:15 Caffeic acid derivatives and tetraenes from Echinacea purpurea alter the
100 expression and not the activity of ABCB1
C. Awortwe, M. Kaehler, H. Bruckmüller, I. Cascorbi (Kiel/DE)
10:45–11:30 Plenary lecture III – Toxicology
HS 9
10:45 Exploiting the human peptidome for novel antimicrobial and anticancer agents
Frank Kirchhoff (Ulm/DE)
11:45–13:15 Symposium 14
HS 9 Uncertainty of toxicological assessments
Chairs M. Batke (Hannover/DE), R. Buesen (Ludwigshafen/DE)
11:45 Identifying and addressing uncertainty in toxicological databases and in silico
models to improve regulatory acceptance
M. Cronin (Liverpool/GB)
12:07 Quality assessment of in vivo studies and data bases
M. Wehr (Hannover/DE)
12:29 Confidence in AOPs and the in vitro methods populating them
S. Hoffmann (Paderborn/DE)
12:51 Quantifying the borderline range and implications for decision-making
M. Mathea (Ludwigshafen/DE)
35Scientific programme • thursday, 5 March
11:45–13:15 Symposium 15
HS 2 RNAs as pharmacological drugs or targets
Chairs A. Aigner (Leipzig/DE), S. Hüttelmaier (Halle a. d. S./DE)
11:45 Development of noncoding RNA therapeutics for cardiac disease
T. Thum (Hannover/DE)
12:15 Systemic mRNA vaccines for cancer immunotherapy
J. Diekmann (Mainz/DE)
12:45 RNA binding proteins and microRNAs – from pharmacological targets to
novel therapeutic strategies
S. Hüttelmaier (Halle a. d. S./DE)
11:45–13:15 Symposium 16
HS 4 Joint SPS/DGPT symposium on the translation of advanced
therapy medicinal products
Chairs W.-H. Zimmermann (Göttingen/DE), F. Hock (Dieburg/DE)
11:45 The Genentech story – all started with somatostatin
D. Stevens (San Francisco, CA/US)
12:07 Genome editing in duchenne muscular dystrophy
C. Kupatt (Munich/DE)
12:29 Development of ATMPs for rare diseases
G. Carey (Boston, MA/US)
12:51 Remuscularization of the failing heart – from bench to bedside
W.-H. Zimmermann (Göttingen/DE)
11:45–13:15 Symposium 17
HS 10 Cannabis and cannabinoids – regulatory framework, research and clinical
experience
Chairs P. Cremer-Schaeffer (Bonn/DE), B. Hinz (Rostock/DE)
11:45 Cannabis-based medicinal products in a specific regulatory framework
P. Cremer-Schaeffer (Bonn/DE)
12:15 Cannabinoids – a pharmacological perspective
B. Hinz (Rostock/DE)
12:45 Implications of cannabinoid receptors in neuropsychiatric disorders
U. Havemann-Reinecke (Göttingen/DE)
36You can also read
